Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05824494 | Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | unknown | Phase 2 | 58 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05841992 | Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05430906 | AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer | unknown | Phase 2 | 40 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03774901 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma(PULSE) | unknown | Phase 2 | 32 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05819060 | The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT03280667 | Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma(KEYPAD) | unknown | Phase 2 | 59 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT03410784 | Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer(MITO28MaNGOov4) | unknown | Phase 2 | 72 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04091204 | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study(MITO 31) | unknown | Phase 2 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05233982 | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer(MITO 35a) | unknown | Phase 2 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04543110 | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC(RADIANT) | unknown | Phase 2 | 16 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05775874 | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | unknown | Phase 2 | 80 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05761132 | Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study(Apollo) | unknown | Phase 2 | 40 | Leiden University Medical CenterOTHER | 0 | Mar 9, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04799847 | Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | unknown | Phase 1 / Phase 2 | 161 | LintonPharm Co.,Ltd.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03321188 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | unknown | Phase 2 | 20 | Andrea JewellOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05453825 | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | unknown | Phase 2 | 180 | OncXerna Theraputics, Inc.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT03845751 | EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.(ENHANCE) | unknown | Phase 2 | 20 | Institut Mutualiste MontsourisOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05249712 | Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer | unknown | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02125513 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer(GOGER-01) | unknown | Phase 2 | 129 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05445648 | Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer(CBPTMI) | unknown | Phase 2 | 65 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05667636 | Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP(esSBRT) | unknown | Phase 2 | 103 | Regina Elena Cancer InstituteOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04356430 | Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer | unknown | Phase 2 | 75 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05641506 | A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT04730219 | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma | unknown | Phase 2 | 48 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05597527 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05167175 | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | unknown | Phase 2 | 30 | Hongqian GuoOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03529890 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder(RACE IT) | unknown | Phase 2 | 33 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05038657 | Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).(AURORA) | unknown | Phase 2 | 36 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05285319 | Trial Comparing Radical Radiotherapy to Prostate Only VS Prostate And Pelvic Lymph Nodes in Intermediate And High Risk Prostate Cancer | unknown | Phase 2 | 82 | Cairo UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04796467 | 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients | unknown | Phase 2 / Phase 3 | 50 | Peking Union Medical College HospitalOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2023source: clinicaltrials